Literature DB >> 14527088

Mechanisms of human hepatocarcinogenesis.

William B Coleman1.   

Abstract

The major risk factors and etiological agents responsible for development of hepatocellular carcinoma in humans have been identified and characterized. Among these are chronic infection with hepatitis B virus or hepatitis C virus, exposure to aflatoxin B1, and cirrhosis of any etiology (including alcoholic cirrhosis and cirrhosis associated with genetic liver diseases). Both chronic hepatitis and cirrhosis represent major preneoplastic conditions of the liver as the majority of hepatocellular carcinomas arise in these pathological settings. Hepatocarcinogenesis represents a linear and progressive process in which successively more aberrant monoclonal populations of hepatocytes evolve. Regenerative hepatocytes in focal lesions in the inflamed liver (chronic hepatitis or cirrhosis) give rise to hyperplastic hepatocyte nodules, and these progress to dysplastic nodules, which are thought to be the direct precursor of hepatocellular carcinoma. In most cases, the neoplastic transformation of hepatocytes results from accumulation of genetic damage during the repetitive cellular proliferation that occurs in the injured liver in response to paracrine growth factor and cytokine stimulation. Hepatocellular carcinomas exhibit numerous genetic abnormalities (including chromosomal deletions, rearrangements, aneuploidy, gene amplifications, and mutations), as well as epigenetic alterations (including modulation of DNA methylation). These genetic and epigenetic alterations combine to activate positive mediators of cellular proliferation (including cellular proto-oncogenes and their mitogenic signaling pathways) and inactivate negative mediators of cellular proliferation (including tumor suppressor genes), resulting in cells with autonomous growth potential. However, hepatocellular carcinomas exhibit a high degree of genetic heterogeneity, suggesting that multiple molecular pathways may be involved in the genesis of subsets of hepatocellular neoplasms. Continued investigation of the mechanisms of hepatocarcinogenesis will refine our current understanding of the molecular and cellular basis for neoplastic transformation in liver, enabling the development of effective strategies for prevention and/or more effective treatment of hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2003        PMID: 14527088     DOI: 10.2174/1566524033479546

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  62 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

Review 2.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

3.  Lack of association of EPHX1 gene polymorphisms with risk of hepatocellular carcinoma: a meta-analysis.

Authors:  Chen-Yang Duan; Meng-Ying Liu; Shao-bo Li; Kuan-sheng Ma; Ping Bie
Journal:  Tumour Biol       Date:  2013-08-17

4.  MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.

Authors:  Zhongwei Cao; Hua Fan-Minogue; David I Bellovin; Aleksey Yevtodiyenko; Julia Arzeno; Qiwei Yang; Sanjiv Sam Gambhir; Dean W Felsher
Journal:  Cancer Res       Date:  2011-01-24       Impact factor: 12.701

5.  Establishment of an orthotopic transplantation tumor model of hepatocellular carcinoma in mice.

Authors:  Gui-Jun Zhao; Li-Xia Xu; Eagle S H Chu; Ning Zhang; Jia-Yun Shen; Alatangaole Damirin; Xiao-Xing Li
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

6.  Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone.

Authors:  Johanna G Miquet; Thomas Freund; Carolina S Martinez; Lorena González; María E Díaz; Giannina P Micucci; Elsa Zotta; Ravneet K Boparai; Andrzej Bartke; Daniel Turyn; Ana I Sotelo
Journal:  Cell Cycle       Date:  2013-02-21       Impact factor: 4.534

7.  Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis.

Authors:  Xiaozhen Zhang; Astrid C Frank; Christine M Gille; Marybeth Daucher; Juraj Kabat; Steven Becker; Richard A Lempicki; Karoll J Cortez; Michael A Polis; G Mani Subramanian; Shyam Kottilil
Journal:  Hepatol Res       Date:  2009-09-25       Impact factor: 4.288

8.  The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Authors:  Patrick J Klein; C Max Schmidt; Chad A Wiesenauer; Jennifer N Choi; Earl A Gage; Michele T Yip-Schneider; Eric A Wiebke; Yufang Wang; Charles Omer; Judith S Sebolt-Leopold
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

9.  Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma.

Authors:  Jian-Min Wu; Yan Xu; Nicholas J Skill; Hongmiao Sheng; Zhenwen Zhao; Menggang Yu; Romil Saxena; Mary A Maluccio
Journal:  Mol Cancer       Date:  2010-03-31       Impact factor: 27.401

10.  Characteristic gene expression profiles in the progression from liver cirrhosis to carcinoma induced by diethylnitrosamine in a rat model.

Authors:  Yue-Fang Liu; Bin-Shan Zha; Hui-Lin Zhang; Xiao-Jing Zhu; Yu-Hua Li; Jin Zhu; Xiao-Hong Guan; Zhen-Qing Feng; Jian-Ping Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.